Last reviewed · How we verify
Simvastatin combined with Amlodipine besylate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Simvastatin combined with Amlodipine besylate (Simvastatin combined with Amlodipine besylate) — Third Military Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Simvastatin combined with Amlodipine besylate TARGET | Simvastatin combined with Amlodipine besylate | Third Military Medical University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Simvastatin combined with Amlodipine besylate CI watch — RSS
- Simvastatin combined with Amlodipine besylate CI watch — Atom
- Simvastatin combined with Amlodipine besylate CI watch — JSON
- Simvastatin combined with Amlodipine besylate alone — RSS
Cite this brief
Drug Landscape (2026). Simvastatin combined with Amlodipine besylate — Competitive Intelligence Brief. https://druglandscape.com/ci/simvastatin-combined-with-amlodipine-besylate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab